Categories: Clinical TrialNews

ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

AI-Driven Enhancements in ObvioGo 2.2 Redefine Efficiency, Compliance, and Innovation in Clinical Trial Management 

NEW YORK, Jan. 14, 2025 /PRNewswire/ — ObvioHealth, a global leader in digital clinical trial solutions, today announced the release of ObvioGo 2.2, the latest version of its innovative platform. This release introduces advanced functionalities designed to streamline study management by leveraging artificial intelligence, enhanced interoperability, and a no-code environment for seamless integration with existing systems and AI models.

ObvioGo 2.2 offers powerful new workflow and task management tools to streamline and enhance trial operations. With real-time compliance tracking and reporting, study teams can proactively identify and address adverse events (AEs), protocol deviations, and compliance risks as they arise, simplifying study management and improving overall efficiency. ObvioGo’s unified platform, now integrating real-time tracking, reporting, and a centralized data repository, unlocks new and novel AI capabilities. It enables seamless integration with existing AI models and the deployment of agentic functionalities, revolutionizing clinical trial efficiency, compliance, and safety.

“ObvioGo 2.2 represents a fundamental shift in clinical trial management, setting a new standard for efficiency and innovation” said Ivan Jarry, CEO of ObvioHealth. “By integrating AI-ready capabilities and seamless connectivity, we are redefining operational efficiency and ensuring data and tasks are organized and accessible for study teams. This release sets a new standard for delivering smarter, faster, and more reliable clinical research outcomes.”

These enhancements simplify the study manager’s role by organizing tasks and data in real-time, paving the way for more efficient and effective trial management. ObvioGo 2.2 underscores ObvioHealth’s commitment to innovation, positioning the company as a leader in AI-driven clinical trial solutions. With its robust capabilities, the platform meets the growing demand for efficient, scalable, and tech-enabled research solutions, delivering significant value to sponsors and advancing the future of clinical research.

About ObvioHealth

ObvioHealth is a global leader in digital clinical trial solutions, delivering smarter, faster, and more cost-effective trials through its innovative ObvioGo platform. By integrating advanced technology with patient-centric design, ObvioHealth ensures high-quality data collection and transformative outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/obviohealth-introduces-obviogo-2-2-transforming-study-management-with-ai-driven-innovation-302349730.html

SOURCE ObvioHealth

Staff

Recent Posts

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

39 minutes ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

39 minutes ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

39 minutes ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

39 minutes ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation…

40 minutes ago

Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings,…

40 minutes ago